Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 18 phantom stock units through the company's Supplemental Savings Plan.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., filed a Form 4 to report changes in beneficial ownership.
• The report indicates that Bourla acquired 18 phantom stock units on October 15, 2024, through the Pfizer Supplemental Savings Plan (SSP).
• Each unit represents one phantom share of Pfizer common stock.
• The price of the phantom stock units was $29.44.
• Following the reported transaction, Bourla directly owns 679,044 derivative securities.
• The phantom stock units are settled in cash upon Bourla's separation from service and can be transferred into an alternative investment account at any time.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.

Positives

• The acquisition of phantom stock units aligns the CEO's interests with the company's performance.
• The Supplemental Savings Plan provides a mechanism for executives to accumulate wealth tied to the company's stock.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Phantom stock units are a common form of executive compensation, aligning management's interests with shareholder value.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects executive compensation and alignment of interests.

Key Dates